A single dose of unadjuvanted novel 2009 H1N1 vaccine is immunogenic and well tolerated in young and elderly adults.

@article{Talaat2010ASD,
  title={A single dose of unadjuvanted novel 2009 H1N1 vaccine is immunogenic and well tolerated in young and elderly adults.},
  author={Kawsar R. Talaat and Michael E. Greenberg and Michael H.-L. Lai and Gunter F. Hartel and Christine H Wichems and Steven Rockman and Robert J Jeanfreau and Malay Ghosh and Martin L. Kabongo and Charmaine Gittleson and Ruth A. Karron},
  journal={The Journal of infectious diseases},
  year={2010},
  volume={202 9},
  pages={1327-37}
}
BACKGROUND When the novel H1N1 influenza A strain appeared in April of 2009, development of novel H1N1 vaccines became a public health priority. METHODS We conducted a phase‐2, multicenter, randomized, placebo‐controlled, observer‐blind clinical trial of a 2009 H1N1 vaccine in 1313 young (age, 18-64 years) and older (age, >or=65 years) adults. Participants were randomized 1:4:4:4 to receive 2 doses of placebo or 7.5, 15, or 30 μg of H1N1 hemagglutinin administered 21 days apart. In post hoc… CONTINUE READING